The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Landscape of EGFR-dependent and independent mechanisms of osimertinib resistance in EGFR-mutant NSCLC patients.
 
Xiuning Le
No Relationships to Disclose
 
Sonam Puri
No Relationships to Disclose
 
Marcelo Vailati Negrao
No Relationships to Disclose
 
Monique B. Nilsson
No Relationships to Disclose
 
Jacqulyne Ponville Robichaux
No Relationships to Disclose
 
Theresa A. Boyle
Other Relationship - Bristol-Myers Squibb
 
James Kevin Hicks
No Relationships to Disclose
 
Emily Roarty
No Relationships to Disclose
 
Waree Rinsurongkawong
No Relationships to Disclose
 
Bonnie S. Glisson
Research Funding - Abbvie/Stemcentrx (Inst); Bristol-Myers Squibb (Inst); ISA Pharmaceuticals (Inst); Medimmune (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Abbvie/Stemcentrx; ISA Pharmaceuticals
 
Jianjun Zhang
Honoraria - Roche; Sino-USA Biomedical Platform
Consulting or Advisory Role - AstraZeneca
 
Vassiliki Papadimitrakopoulou
Consulting or Advisory Role - ARIAD; AstraZeneca; Biothera; Clovis Oncology; Genentech; Genentech; Gensignia Life Sciences; Janssen; Lilly; Merck; Nektar
Research Funding - ACEA Biosciences (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
 
Jhanelle Elaine Gray
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Celgene; Genentech/Roche; Janssen; Lilly
Speakers' Bureau - Genentech
Research Funding - Array BioPharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Epic Sciences (Inst); Genentech/Roche (Inst); Merck (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Genentech/Roche; Janssen Oncology
 
John Heymach
Stock and Other Ownership Interests - Bio-Tree; Cardinal Spine
Consulting or Advisory Role - Abbvie; ARIAD; AstraZeneca; AstraZeneca; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Calithera Biosciences; Genentech; Medivation; Novartis; Oncomed; Synta
Research Funding - AstraZeneca (Inst)